INTRODUCTION: Sexual dysfunction has only recently been recognized as a highly prevalent side effect of adjuvant aromatase inhibitor (AI) therapy for breast cancer. AIMS: A cross-sectional survey using standardized measures of female sexual function was designed to provide a detailed view of sexual problems during the first 2 years of adjuvant AI therapy and secondarily to examine whether sexual dysfunction leads to nonadherence to this therapy. METHODS: Questionnaires were mailed to all 296 women in a breast oncology registry who had been prescribed a first-time AI for localized breast cancer 18-24 months previously. MAIN OUTCOME MEASURES: Items assessed medication adherence, demographic, and medical information. Scales included the Female Sexual Function Index, the Menopausal Sexual Interest Questionnaire, the Female Sexual Distress Scale-Revised, the Breast Cancer Prevention Trial Eight Symptom Scale to assess menopausal symptoms, and the Merck Adherence Estimator(®) . RESULTS: Questionnaires were returned by 129 of 296 eligible women (43.6%). Respondents were 81% non-Hispanic white with a mean age of 63 and 48% had at least a college degree. Only 15.5% were nonadherent. Ninety-three percent of women scored as dysfunctional on the Female Sexual Function Index, and 75% of dysfunctional women were distressed about sexual problems. Although only 52% of women were sexually active when starting their AI, 79% of this group developed a new sexual problem. Fifty-two percent took action to resolve it, including 24% who stopped partner sex, 13% who changed hormone therapies, and 6% who began a vaginal estrogen. Scores on the Adherence Estimator (beliefs about efficacy, value, and cost of medication) were significantly associated with adherence (P = 0.0301) but sexual function was not. CONCLUSIONS: The great majority of women taking AIs have sexual dysfunction that is distressing and difficult to resolve. Most continue their AI therapy, but a large minority cease sexual activity.
INTRODUCTION:Sexual dysfunction has only recently been recognized as a highly prevalent side effect of adjuvant aromatase inhibitor (AI) therapy for breast cancer. AIMS: A cross-sectional survey using standardized measures of female sexual function was designed to provide a detailed view of sexual problems during the first 2 years of adjuvant AI therapy and secondarily to examine whether sexual dysfunction leads to nonadherence to this therapy. METHODS: Questionnaires were mailed to all 296 women in a breast oncology registry who had been prescribed a first-time AI for localized breast cancer 18-24 months previously. MAIN OUTCOME MEASURES: Items assessed medication adherence, demographic, and medical information. Scales included the Female Sexual Function Index, the Menopausal Sexual Interest Questionnaire, the Female Sexual Distress Scale-Revised, the Breast Cancer Prevention Trial Eight Symptom Scale to assess menopausal symptoms, and the Merck Adherence Estimator(®) . RESULTS: Questionnaires were returned by 129 of 296 eligible women (43.6%). Respondents were 81% non-Hispanic white with a mean age of 63 and 48% had at least a college degree. Only 15.5% were nonadherent. Ninety-three percent of women scored as dysfunctional on the Female Sexual Function Index, and 75% of dysfunctionalwomen were distressed about sexual problems. Although only 52% of women were sexually active when starting their AI, 79% of this group developed a new sexual problem. Fifty-two percent took action to resolve it, including 24% who stopped partner sex, 13% who changed hormone therapies, and 6% who began a vaginal estrogen. Scores on the Adherence Estimator (beliefs about efficacy, value, and cost of medication) were significantly associated with adherence (P = 0.0301) but sexual function was not. CONCLUSIONS: The great majority of women taking AIs have sexual dysfunction that is distressing and difficult to resolve. Most continue their AI therapy, but a large minority cease sexual activity.
Authors: David Cella; Lesley Fallowfield; Peter Barker; Jack Cuzick; Gershon Locker; Anthony Howell Journal: Breast Cancer Res Treat Date: 2006-06-21 Impact factor: 4.872
Authors: Alan S Coates; Aparna Keshaviah; Beat Thürlimann; Henning Mouridsen; Louis Mauriac; John F Forbes; Robert Paridaens; Monica Castiglione-Gertsch; Richard D Gelber; Marco Colleoni; István Láng; Lucia Del Mastro; Ian Smith; Jacquie Chirgwin; Jean-Marie Nogaret; Tadeusz Pienkowski; Andrew Wardley; Erik H Jakobsen; Karen N Price; Aron Goldhirsch Journal: J Clin Oncol Date: 2007-01-02 Impact factor: 44.544
Authors: David Cella; Stephanie R Land; Chih-Hung Chang; Richard Day; Joseph P Costantino; Norman Wolmark; Patricia A Ganz Journal: Breast Cancer Res Treat Date: 2007-09-13 Impact factor: 4.872
Authors: Stephen E Jones; James Cantrell; Svetislava Vukelja; John Pippen; Joyce O'Shaughnessy; Joanne L Blum; Robert Brooks; Nicole L Hartung; Angel G Negron; Donald A Richards; Ragene Rivera; Frankie Ann Holmes; Sreeni Chittoor; Thomas L Whittaker; James H Bordelon; Steven J Ketchel; Jennifer C Davis; Des Ilegbodu; Jean Kochis; Lina Asmar Journal: J Clin Oncol Date: 2007-10-20 Impact factor: 44.544
Authors: Jennifer Barsky Reese; Kristen Sorice; Stephen J Lepore; Mary B Daly; James A Tulsky; Mary Catherine Beach Journal: Patient Educ Couns Date: 2018-10-04
Authors: Stacy Tessler Lindau; Emily M Abramsohn; Shirley R Baron; Judith Florendo; Hope K Haefner; Anuja Jhingran; Vanessa Kennedy; Mukta K Krane; David M Kushner; Jennifer McComb; Diane F Merritt; Julie E Park; Amy Siston; Margaret Straub; Lauren Streicher Journal: CA Cancer J Clin Date: 2016-01-19 Impact factor: 508.702
Authors: Maria Ida Maiorino; Paolo Chiodini; Giuseppe Bellastella; Dario Giugliano; Katherine Esposito Journal: Endocrine Date: 2015-12-07 Impact factor: 3.633